Correspondence 0001213900-23-057717 from ENZO BIOCHEM INC (ENZ) (CIK 0000316253)
ENZO BIOCHEM INC (ENZ) (CIK 0000316253)
Date: July 18, 2023 · CIK: 0000316253 · Accession: 0001213900-23-057717
AI Filing Summary & Sentiment
File numbers found in text: 333-272727
Letter
VIA EDGAR AND EMAIL Division of Corporation Finance Office of Industrial Applications and Services Attention: ENZO BIOCHEM INC Amendment No. 1 to Registration Statement on Form S-3 Filed July 10, 2023 File No. 333-272727
Dear Ms. Ansart and Ms. Bagley:
I am writing to submit the responses of Enzo Biochem, Inc. (the “Company”) to the comments of the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) dated July 14, 2023 (the “Comment Letter”), relating to the above referenced Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-272727) filed by the Company on July 10, 2023 ( “Amendment No. 1”).
Concurrent with the submission of this letter, the Company is filing via EDGAR Amendment No. 2 to the Registration Statement (“Amendment No. 2”), which reflects the Company’s responses to the comments received by the Staff and certain updated information. I have also enclosed a courtesy copy of Amendment No. 2, marked to indicate changes from Amendment No. 1, as Exhibit A. For your convenience, the Company is also delivering via email a copy of this letter and its enclosures.
For ease of review, I have set forth below each of the numbered comments of your letter and the Company’s responses thereto. Capitalized terms used herein but not defined herein have the meanings given to such terms in Amendment No. 2.
Amendment No. 1 to Registration Statement on Form S-3
Cover Page
1. We note your amended disclosure in response to comments 1 and 2, including that the occurrence of an event of default, including failing to consummate the asset sale, may result in the acceleration of the your obligations under the Debentures, and if this were to occur, you may neither have sufficient cash on hand nor have access to liquidity to be able to repay such obligations, which could result in you pursuing, among other options, bankruptcy and liquidation. Please amend your disclosure to clarify the impact on equity holders if you were to file for bankruptcy, including whether equity holders could expect any recovery in bankruptcy.
Response: In response to the Staff’s comment, we have revised our Cover Page to clarify that our equity holders would likely receive no recovery at all in the case of a bankruptcy or liquidation. We have also added this disclosure to the Summary section on page 3, two Risk Factors on page 6, and the Private Placement of Securities section on page 14.
Please contact me at (631) 755-5500 if you have any questions or require any additional information in connection with this letter.
Sincerely,
/s/ Hamid Erfanian
Show Raw Text
CORRESP
1
filename1.htm
July 18, 2023
VIA EDGAR AND EMAIL
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jessica Ansart
Katherine Bagley
Re:
ENZO BIOCHEM INC
Amendment No. 1 to Registration Statement on
Form S-3
Filed July 10, 2023
File No. 333-272727
Dear Ms. Ansart and Ms. Bagley:
I am writing to submit the responses of Enzo Biochem,
Inc. (the “Company”) to the comments of the staff (the “Staff”) of the Division of Corporation Finance of the
Securities and Exchange Commission (the “Commission”) dated July 14, 2023 (the “Comment Letter”), relating to
the above referenced Amendment No. 1 to Registration Statement on Form S-3 (File No. 333-272727) filed by the Company on July 10, 2023
( “Amendment No. 1”).
Concurrent with the submission of this letter,
the Company is filing via EDGAR Amendment No. 2 to the Registration Statement (“Amendment No. 2”), which reflects the Company’s
responses to the comments received by the Staff and certain updated information. I have also enclosed a courtesy copy of Amendment No.
2, marked to indicate changes from Amendment No. 1, as Exhibit A. For your convenience, the Company is also delivering via email a copy
of this letter and its enclosures.
For ease of review, I have set forth below each
of the numbered comments of your letter and the Company’s responses thereto. Capitalized terms used herein but not defined herein
have the meanings given to such terms in Amendment No. 2.
Amendment No. 1 to Registration Statement on
Form S-3
Cover Page
1.
We note your amended disclosure in response to comments 1 and 2, including that the occurrence of an event of default, including failing to consummate the asset sale, may result in the acceleration of the your obligations under the Debentures, and if this were to occur, you may neither have sufficient cash on hand nor have access to liquidity to be able to repay such obligations, which could result in you pursuing, among other options, bankruptcy and liquidation. Please amend your disclosure to clarify the impact on equity holders if you were to file for bankruptcy, including whether equity holders could expect any recovery in bankruptcy.
Response: In response to the Staff’s
comment, we have revised our Cover Page to clarify that our equity holders would likely receive no recovery at all in the case of a bankruptcy
or liquidation. We have also added this disclosure to the Summary section on page 3, two Risk Factors on page 6, and the Private Placement
of Securities section on page 14.
Please contact me at (631) 755-5500 if you have
any questions or require any additional information in connection with this letter.
Sincerely,
/s/ Hamid Erfanian
Hamid Erfanian, Chief Executive Officer
cc: Dan Woodard, McDermott Will & Emery